Table 1 Supplementary: Hazard ratio between the presence of adverse effects from vaccination with the fourth dose against COVID-19 and the variables of interest in adults over 40 years of age in Trujillo, Peru.

|  |  |  |  |
| --- | --- | --- | --- |
|  | HR | 95% CI | p-value |
| Age (years) |  |  |  |
| <60 | Ref. |  |  |
| ≥60 | 0.77 | 0.67 – 0.89 | **<0.001** |
| Sex |  |  |  |
| Female | Ref. |  |  |
| Male | 0.88 | 0.77 – 1.00 | **0.060** |
| vaccination scheme |  |  |  |
| Counterpart | Ref. |  |  |
| heterologous | 1.09 | 0.96 – 1.23 | 0.198 |
| BMI |  |  |  |
| normal weight | Ref. |  |  |
| Overweight | 0.96 | 0.82 – 1.13 | 0.636 |
| Obesity | 0.94 | 0.78 – 1.13 | 0.533 |
| Previous infection by COVID-19 |  |  |  |
| No | Ref. |  |  |
| Yes | 1.11 | 0.97 – 1.27 | 0.144 |
| Simultaneous vaccination against influenza |  |  |  |
| No | Ref. |  |  |
| Yes | 1.20 | 1.04 – 1.40 | **0.016** |
| Presence of comorbidities |  |  |  |
| No | Ref. |  |  |
| Yes | 1.06 | 0.90 – 1.23 | 0.516 |
| Last vaccine |  |  |  |
| mRNA-1273 (Moderna) | Ref. |  |  |
| BNT162b2 (Pfizer-BioNtech) | 0.78 | 0.55 – 1.11 | 0.169 |
| Previous BBIBP-CorV |  |  |  |
| No | Ref. |  |  |
| Yes | 1.14 | 1.01 – 1.30 | **0.049** |

HR: Hazard Ratio. CI: confidence interval; Ref: Reference